Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03339089
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:35.506309+00:00
Published At
2022-07-08T00:00:00+00:00
Record Updated At
2022-07-08
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Ankylosing Spondylitis (AS)", "Psoriasis", "Rheumatoid Arthritis (RA)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-07-08"
protocolSection.identificationModule.nctId
"NCT03339089"
protocolSection.identificationModule.officialTitle
"Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
[]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Ankylosing Spondylitis (AS) (protocolSection.conditionsModule.conditions)
  • Psoriasis (protocolSection.conditionsModule.conditions)
  • Rheumatoid Arthritis (RA) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.